Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/18107
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTrubiano, Jason-
dc.contributor.authorThursky, Karin A-
dc.contributor.authorStewardson, Andrew J-
dc.contributor.authorUrbancic, Karen-
dc.contributor.authorWorth, Leon J-
dc.contributor.authorJackson, Cheryl-
dc.contributor.authorStevenson, Wendy-
dc.contributor.authorSutherland, Michael F-
dc.contributor.authorSlavin, Monica A-
dc.contributor.authorGrayson, M Lindsay-
dc.contributor.authorPhillips, Elizabeth J-
dc.date.accessioned2018-07-22T23:25:46Z-
dc.date.available2018-07-22T23:25:46Z-
dc.date.issued2017-07-01-
dc.identifier.citationClinical Infectious Diseases 2017; 65(1): 166-174-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/18107-
dc.description.abstractDespite the high prevalence of patient-reported antibiotic allergy (so-called antibiotic allergy labels [AALs]) and their impact on antibiotic prescribing, incorporation of antibiotic allergy testing (AAT) into antimicrobial stewardship (AMS) programs (AAT-AMS) is not widespread. We aimed to evaluate the impact of an AAT-AMS program on AAL prevalence, antibiotic usage, and appropriateness of prescribing. AAT-AMS was implemented at two large Australian hospitals during a 14-month period beginning May 2015. Baseline demographics, AAL history, age-adjusted Charlson comorbidity index, infection history, and antibiotic usage for 12 months prior to testing (pre-AAT-AMS) and 3 months following testing (post-AAT-AMS) were recorded for each participant. Study outcomes included the proportion of patients who were "de-labeled" of their AAL, spectrum of antibiotic courses pre- and post-AAT-AMS, and antibiotic appropriateness (using standard definitions). From the 118 antibiotic allergy-tested patients, 226 AALs were reported (mean, 1.91/patient), with 53.6% involving 1 or more penicillin class drug. AAT-AMS allowed AAL de-labeling in 98 (83%) patients-56% (55/98) with all AALs removed. Post-AAT, prescribing of narrow-spectrum penicillins was more likely (adjusted odds ratio [aOR], 2.81, 95% confidence interval [CI], 1.45-5.42), as was narrow-spectrum β-lactams (aOR, 3.54; 95% CI, 1.98-6.33), and appropriate antibiotics (aOR, 12.27; 95% CI, 5.00-30.09); and less likely for restricted antibiotics (aOR, 0.16; 95% CI, .09-.29), after adjusting for indication, Charlson comorbidity index, and care setting. An integrated AAT-AMS program was effective in both de-labeling of AALs and promotion of improved antibiotic usage and appropriateness, supporting the routine incorporation of AAT into AMS programs.-
dc.language.isoeng-
dc.subjectallergy testing-
dc.subjectantibiotic allergy-
dc.subjectantimicrobial resistance-
dc.subjectpenicillin allergy-
dc.titleImpact of an Integrated Antibiotic Allergy Testing Program on Antimicrobial Stewardship: A Multicenter Evaluation.-
dc.typeJournal Article-
dc.identifier.journaltitleClinical Infectious Diseases-
dc.identifier.affiliationDepartment of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, Victoria Comprehensive Cancer Centre (VCCC), Parkville, Victoria, Australia-
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Parkville, Victoria, Australia-
dc.identifier.affiliationNational Centre for Antimicrobial Stewardship, Royal Melbourne Hospital, Parkville, Victoria, Australia-
dc.identifier.affiliationCentre for Improving Cancer Outcomes Through Enhanced Infection Services, National Health and Medical Research Council Centre of Research Excellence, Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia-
dc.identifier.affiliationPharmacy Department, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Pharmacy, Peter MacCallum Cancer Centre, VCCC, Parkville-
dc.identifier.affiliationDepartment of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Parkville-
dc.identifier.affiliationInstitute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia-
dc.identifier.affiliationDepartments of Medicine and Pharmacology, Vanderbilt University Medical Centre, Nashville, Tennessee-
dc.identifier.doi10.1093/cid/cix244-
dc.identifier.pubmedid28520865-
dc.type.austinJournal Article-
dc.type.austinMulticenter Study-
dc.type.austinReview-
local.name.researcherGrayson, M Lindsay-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptInfectious Diseases-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptCentre for Antibiotic Allergy and Research-
crisitem.author.deptInfectious Diseases-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

16
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.